Adlai Nortye (NASDAQ:ANL) Shares Down 1.4% – Here’s Why

Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL)’s stock price was down 1.4% on Tuesday . The company traded as low as $1.45 and last traded at $1.45. Approximately 3,767 shares changed hands during trading, a decline of 63% from the average daily volume of 10,192 shares. The stock had previously closed at $1.47.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Adlai Nortye in a report on Wednesday, October 8th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Reduce”.

Adlai Nortye Stock Down 1.4%

The business’s 50 day moving average is $1.58 and its 200-day moving average is $1.62.

Adlai Nortye Company Profile

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.